Matinas BioPharma Holdings, Inc.

Day range

$1.12 – $1.25

Open

$1.22

Prev close

$1.16

Volume

35.66K

Market cap

$1.17M

Shares out

979.52K

P/E

—

P/S

—

P/B

0.65

P/FCF

—

ROE

-406.1%

ROA

-214.2%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 6, 2026

• Deal terminationNov 3, 2026

  On November 3, 2026, Matinas BioPharma Holdings, Inc. (the "Company") and a former financial advisor to the Company (the "Advisor") terminated the agreement between the Company and the Advisor.

• Charter amendmentSep 28, 2026

  On September 25, 2026, Matinas BioPharma Holdings, Inc. ... filed a Certificate of Amendment to the Company's Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware.

• Stock splitSep 16, 2026

  On September 16, 2026, the Company announced that the Board has approved a reverse stock split of the Common Stock at a ratio of one-for-fifteen (1:15) (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on September 28, 2026.

• Listing deficiency noticeSep 4, 2026

  As previously disclosed, the Company also received written notices from the NYSE American indicating that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide.

• Deal terminationJul 24, 2026

  On July 23, 2026, pursuant to and in accordance with Section 12(a) of the Sales Agreement, BTIG notified the Company that BTIG is terminating the Sales Agreement, effective immediately. The Company is not subject to any termination penalties or other expenses related to the termination of the Sales Agreement.

Days to cover

1.0

Short interest

49.43K

Avg volume

129.62K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
  negativeGlobeNewswire Inc.· Sep 4, 2026
• Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
  negativeGlobeNewswire Inc.· Jun 26, 2026
• Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
  GlobeNewswire Inc.· Jun 24, 2024
• Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
  GlobeNewswire Inc.· Jun 13, 2024
• New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
  GlobeNewswire Inc.· May 16, 2024